Valuation: NOVARTIS

Market Cap 282B 247B 228B 210B 399B 26,893B 405B 2,718B 1,067B 13,249B 1,059B 1,036B 45,546B P/E 2026 *
21.5x
P/E 2027 * 18.2x
Enterprise Value 314B 275B 253B 234B 444B 29,948B 451B 3,027B 1,189B 14,753B 1,179B 1,153B 50,719B EV / Sales 2026 *
5.52x
EV / Sales 2027 * 5.15x
Free-Float
91.66%
Yield 2026 *
2.86%
Yield 2027 * 2.95%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+50.33%+162.29% 1,085B
-0.82%-2.30%+62.97%+61.11% 624B
-0.73%-4.98%+27.22%+84.46% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
+0.66%-1.42%-29.26%-39.30% 217B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 167B
-0.33%-0.62%-6.25%-32.26% 138B
Average -0.88%-3.30%+20.90%+46.94% 386.45B
Weighted average by Cap. -0.59%-3.08%+34.53%+80.15%

Financials

2026 *2027 *
Net sales 56.86B 49.74B 45.88B 42.37B 80.4B 5,423B 81.75B 548B 215B 2,672B 214B 209B 9,185B 60.3B 52.74B 48.65B 44.93B 85.26B 5,751B 86.69B 581B 228B 2,833B 226B 221B 9,740B
Net income 14.08B 12.31B 11.36B 10.49B 19.91B 1,343B 20.24B 136B 53.3B 661B 52.86B 51.71B 2,274B 15.64B 13.68B 12.62B 11.66B 22.12B 1,492B 22.49B 151B 59.22B 735B 58.73B 57.46B 2,527B
Net Debt 32.03B 28.01B 25.84B 23.86B 45.28B 3,054B 46.04B 309B 121B 1,505B 120B 118B 5,173B 28.54B 24.96B 23.02B 21.26B 40.35B 2,722B 41.03B 275B 108B 1,341B 107B 105B 4,609B
Logo NOVARTIS
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA